Key result
Percutaneous direct thrombin injection with hydrodissection successfully treated a persistent type II endoleak after EVAR, with no endoleak visible at 6 months.
Why the study?
Does percutaneous direct thrombin injection with hydrodissection resolve type II endoleak in a patient after EVAR?
Case Report (n=1)
No
Does percutaneous direct thrombin injection with hydrodissection resolve type II endoleak in a patient after EVAR?
Percutaneous direct thrombin injection with hydrodissection appears to be a safe and feasible alternative for treating type II endoleak after EVAR when transarterial approaches are unsuccessful.
May offer a minimally invasive option for refractory type II endoleaks after EVAR; leaves open need for prospective validation.
Type II endoleak is the most common complication after endovascular abdominal aortic aneurysm repair (EVAR). The management remains controversial. We present a case in which endoleak was successfully treated by direct percutaneous thrombin injection with hydrodissection. This method seems to be a safe and feasible alternative method for treatment of type II endoleak.
No takes yet. Share an insight, caveat, or question.
Żabicki et al. (2018) conducted a case report in Type II endoleak after EVAR (n=1). Percutaneous direct thrombin injection with hydrodissection was evaluated on Resolution of endoleak. Percutaneous direct thrombin injection with hydrodissection successfully treated a persistent type II endoleak after EVAR, with no endoleak visible at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: